Evaluation of the effects of oxytocin in patients with schizophrenia

Phase 4

• Conditions: Schizophrenia; Healthy volunteers; Obesity; M01.774.500

• Registration Number: RBR-4yr9mt
• Lead Sponsor: Faculdade de Medicina de Ribeirão Preto

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2020-09-22
• Last Update Posted: 29 May 2023

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: Male
• Target Recruitment: Not specified

Inclusion Criteria

General: Men aged 18 to 50 years, literate, signing the Informed Consent Form.
For the clinical group, the participants must have a diagnosis of Refractory Schizophrenia, with a disease duration between 10 and 15 years, be on an outpatient treatment, using Clozapine exclusively and without psychiatric comorbidities.
For the control group, participants must have no current or previous psychiatric disorder and use any psychotropic drugs. For Phase 3 of the study, participants in the control group must be overweight (BMI greater than 25kg / m2).

Exclusion Criteria

For clinical and control group: presence of clinical diseases of great impact on the functioning of the organism, such as degenerative, neurological diseases, cancers, hematological, pulmonary, renal, liver, cardiovascular diseases and / or use of psychoactive substances.
For Phase 3: participants using oral antidiabetics, lipid-lowering drugs, sibutramine, amphetamines, orlistat or other medications for the treatment of excess weight will also be excluded. Participants with schizophrenia who experience any change in their medication or therapeutic prescriptions during the period of participation in the study will be automatically excluded

Study & Design

• Study Type: Intervention
• Study Design: Not specified